Stay updated with breaking news from Lymphoma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.
Over the last decade, determined researchers have made significant progress in the effort to improve treatment options for cancer patients.
Efforts to widen the treatment armamentarium for patients with mantle cell lymphoma have been thwarted by increased toxicities and resistance mechanisms with effective therapies such as BTK inhibitors.
It's difficult to know whether the girl's death was directly related to her socioeconomic status, but it certainly made all aspects of the child's care more complicated.
The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, MD, an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search.